Selumetinib Sulfate Patent Expiration
Selumetinib Sulfate is Used for treating symptomatic, inoperable plexiform neurofibromas in pediatric patients with neurofibromatosis type 1 (NF1) aged 2 years and older. It was first introduced by Astrazeneca Pharmaceuticals Lp
Selumetinib Sulfate Patents
Given below is the list of patents protecting Selumetinib Sulfate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Koselugo | US11813246 | Pharmaceutical composition | Mar 26, 2029 | Astrazeneca |
| Koselugo | US9156795 | Hydrogen sulfate salt | Dec 12, 2026 | Astrazeneca |
| Koselugo | US9562017 | Hydrogen sulfate salt | Dec 12, 2026 | Astrazeneca |
| Koselugo | US7425637 | N3 alkylated benzimidazole derivatives as MEK inhibitors | Mar 13, 2025 | Astrazeneca |
| Koselugo | US8178693 | N3 alkylated benzimidazole derivatives as MEK inhibitors | Mar 13, 2025 | Astrazeneca |
Selumetinib Sulfate's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List